FDA Approves Smart Programmer for Medtronic Neuromodulation System

FDA approved a new smart programmer for Medtronic's InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention. The new programmer streamlines multiple devices into a single, intuitive, touchscreen Samsung mobile device and enables clinicians to personalize each patient's care and allows patients to manage their therapy simply and discreetly, Medtronic said. According to the company, more than 37 million adults in the United States (almost one in six) suffer from OAB and nearly 20 million Americans (about one in 12) have bowel incontinence. "In addition to simplified programming and ongoing management of InterStim therapy, the smart programmer is discreet, which is meaningful to patients because OAB can greatly impact confidence, intimacy, and activities," said Steven Siegel, MD, Metro Urology Centers for Female Urology and Continence Care in Minneapolis, MN. "It takes courage to seek treatment and many struggle to find long-term relief. My goal is to address OAB symptoms and help restore my patients' quality of life, and I'm pleased to have a tool like the InterStim smart programmer for patients who may benefit from neuromodulation." Designed to deliver easy, streamlined programming, the smart programmer provides an app-based platform for implant and long-term therapy management. Physicians can instantly check MRI elig...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news